Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-world First-line Serplulimab-based Immunochemotherapy for Extensive-stage Small Cell Lung Cancer: the Multicenter ASTRUM-005R Study

NCT06748495 is registered in ClinicalTrials.gov with Hunan Cancer Hospital as lead sponsor.

NCT NCT06748495
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06748495 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-world First-line Serplulimab-based Immunochemotherapy for Extensive-stage Small Cell Lung Cancer: the Multicenter ASTRUM-005R Study
Lead sponsor
Hunan Cancer Hospital
Phase
Observational
Overall status
Active, not recruiting
Start date
February 5, 2024
Completion date
June 6, 2025
Enrollment
600 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

extensive-stage small cell lung cancer (es-sclc)